About: AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Sector: Healthcare
Industry: Biotechnology
Latest price: $13.08 (-4.11%)
ABCL NASDAQ Abcellera Biologics Inc
Abcellera Biologics Inc share price
Atividade de preço de ABCL
Último preço
$ 13,080
Variação (24h)
-0,56 USD (4,11%)
Volume
2.56M
Volume (média 4 sem.)
-
Abertura
$ 13,41
Variação do dia
$ 13,02 - $ 13,86
Fechamento anterior
$ 13,64
Último negócio
29 Oct, 8:21 pm GMT+0
Atrasado
29 Oct, 8:21 pm GMT+0
ABCL price performance
Atrasado
29 Oct, 8:21 pm GMT+0
quote.marketSignals